Summit Therapeutics Inc.
SMMT
$15.12
$0.251.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 306.11M | 603.76M | 556.75M | 493.35M | 410.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 874.84M | 1.22B | 1.09B | 935.11M | 759.28M |
| Operating Income | -874.84M | -1.22B | -1.09B | -935.11M | -759.28M |
| Income Before Tax | -856.09M | -1.21B | -1.08B | -921.62M | -746.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -856.09 | -1.21K | -1.08K | -921.62 | -746.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -856.09M | -1.21B | -1.08B | -921.62M | -746.08M |
| EBIT | -874.84M | -1.22B | -1.09B | -935.11M | -759.28M |
| EBITDA | -874.67M | -1.22B | -1.09B | -934.99M | -759.18M |
| EPS Basic | -1.12 | -1.60 | -1.44 | -1.24 | -1.01 |
| Normalized Basic EPS | -0.70 | -1.00 | -0.90 | -0.78 | -0.63 |
| EPS Diluted | -1.12 | -1.60 | -1.45 | -1.25 | -1.02 |
| Normalized Diluted EPS | -0.70 | -1.00 | -0.90 | -0.78 | -0.63 |
| Average Basic Shares Outstanding | 3.06B | 3.03B | 2.99B | 2.96B | 2.94B |
| Average Diluted Shares Outstanding | 3.06B | 3.03B | 2.99B | 2.96B | 2.94B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |